The Recovery Protocol

BPC-157 upregulates VEGF expression and promotes angiogenesis in damaged tissue — it builds the blood supply that repair depends on. TB-500, the active fragment of thymosin beta-4, works one layer up: actin regulation and cell migration, moving repair cells to where the damage is. Run together, they cover both halves of the repair equation. Most people run BPC-157 solo, underdose it, and quit before remodeling has started. That's leaving results on the table.

This protocol is for people carrying something that won't resolve — the tendinopathy that survives every deload, the pulled muscle that's three months old, the gut that never quite settled. Expect gradual change, not a switch: tissue remodeling shows up in weeks 3–6, not days. The effort is real — daily subcutaneous injections, consistent timing, and an 8-week commitment. If you want a painkiller, this isn't one.

What makes it a protocol rather than a shopping list: exact reconstitution math, a week-by-week injection calendar, a bloodwork panel to run before and after, a side-effect table, and defined exit criteria so you know when you're done. One flag we don't bury: both compounds are angiogenic, so anyone with a cancer history should sit this one out entirely.